A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma



Status:Recruiting
Conditions:Lymphoma, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 99
Updated:3/15/2019
Start Date:November 15, 2017
End Date:October 2021
Contact:William Reed, MD
Email:clinicaltrials@beigene.com
Phone:781-801-1800

Use our guide to learn which trials are right for you!

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma

The purpose of the study is to evaluate the efficacy, safety and tolerability and of
BGB-3111plus obinutuzumab versus obinutuzumab alone in subjects with relapsed/refractory
non-Hodgkin follicular lymphoma.

This is an open-label, randomized active control study of BGB-3111 plus obinutuzumab versus
obinutuzumab alone in subjects with relapsed or refractory follicular lymphoma. Randomization
is 2:1 and subjects will be stratified by the number of prior lines of therapy (2 - 3 vs > 3)
and rituximab-refractory status. The study will evaluate the efficacy, as measured by overall
response rate by independent review, safety and tolerability. Pharmacokinetic profile of
BGB-3111 and obinutuzumab combination therapy will also be evaluated.

Inclusion Criteria: All subjects

1. Histologically confirmed diagnosis of B-cell follicular lymphoma based on the WHO 2008
classification of tumors of hematopoietic and lymphoid tissue.

2. ≥2 prior systemic treatments for follicular lymphoma.

3. Previously received an anti-CD20 antibody and an appropriate alkylator-based
combination therapy.

4. Disease progression within 12 months after completion of most recent therapy or
refractory disease.

5. Presence of measurable disease.

6. Availability of archival tissue confirming diagnosis.

7. ECOG performance status of 0,1 or 2.

8. Life expectancy ≥6 months.

9. Adequate bone marrow function.

10. Adequate renal and hepatic function.

11. Females of childbearing potential and non-sterile males must agree to use highly
effective methods of birth control throughout the course of study and at least up to
90 days after last dosing, or 18 months after the last dose of obinutuzumab, whichever
is longer.

12. Male subjects are eligible if vasectomized or if they agree to the use of barrier
contraception in combination with other methods during the study treatment period and
for ≥ 90 days after the last dose of BGB-3111.

13. Ability to provide the written informed consent and can understand and comply with the
requirements of the study.

Exclusion Criteria: All subjects

1. Prior exposure to a BTK inhibitor.

2. Known central nervous system involvement by leukemia or lymphoma.

3. No evidence of transformation from follicular lymphoma to other aggressive histology.

4. No allogeneic hematopoietic stem cell transplantation within 12 months of enrollment

5. Prior malignancy within the past 5 years, except for basal or squamous cell skin
cancer, superficial bladder cancer, carcinoma in situ of the cervix of breast, or
localized Gleason score 6 prostate

6. Clinically significant cardiovascular disease.

7. Major surgery or significant injury ≤ 4 weeks prior to start of study treatment.

8. Active fungal, bacterial or viral infection requiring systemic treatment.

9. History of severe bleeding disorder.

10. History of stroke or intracranial hemorrhage within 6 months before first study drug.

11. Severe or debilitating pulmonary disease.

12. Known human immunodeficiency virus (HIV) or active hepatitis B or C.

13. Unable to swallow capsules or significant gastrointestinal disease that would
interfere with drug absorption.

14. Requires ongoing treatment with a strong CYP3A inhibitor or inducer

15. Pregnant or nursing females.

16. Vaccination with live vaccine within 35 days prior to first dose.

17. Ongoing drug or alcohol addiction.

18. Hypersensitivity to BGB-3111, known ingredients of BGB-3111 or obinutuzumab.

19. Participation in another therapeutic trial.
We found this trial at
9
sites
Florham Park, New Jersey 07932
Principal Investigator: Charles Farber, MD
?
mi
from
Florham Park, NJ
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Jonathon Cohen, MD
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bethesda, Maryland 20817
Principal Investigator: Ralph Boccia, MD
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: John Galvin, MD
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Concord, New South Wales
Principal Investigator: Judith Trotman, MD
?
mi
from
Concord,
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Matthew McKinney, MD
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
Principal Investigator: Nathan Fowler, MD
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Las Vegas, Nevada 89169
Principal Investigator: Edwin Kingsley, MD
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
2160 South 1st Avenue
Maywood, Illinois 60153
(888) 584-7888
Principal Investigator: Scott Smith, MD
Loyola University Medical Center Loyola University Health System is committed to excellence in patient care...
?
mi
from
Maywood, IL
Click here to add this to my saved trials